Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

In this segment, faculty discuss long-term safety considerations associated with lorlatinib treatment in ALK-positive NSCLC. The panel reviews adverse events reported during extended follow-up, including hyperlipidemia, weight gain, edema, and neurocognitive effects, and discusses approaches to monitoring and management in clinical practice. Faculty describe strategies for dose modifications, supportive care interventions, and patient education throughout treatment. The discussion also addresses the role of multidisciplinary care and caregiver involvement when evaluating cognitive and behavioral changes that may occur during therapy. In addition, panelists review factors that may influence decisions regarding treatment continuation and long-term management. The segment provides an overview of safety considerations associated with prolonged ALK inhibitor therapy.